
S6 E12: Anti-Ds for Insomnia; SSRIs & Hypotension; Cancer Cures
NB Hot Topics Podcast
00:00
Promising Advances in Cancer Treatment with Dostalimab
This chapter explores a groundbreaking trial of dostalimab for patients with solid tumors that have mismatch repair deficiency, showcasing an impressive 84% complete clinical response rate. With a favorable side effect profile and high recurrence-free survival, the findings suggest a transformative shift in cancer treatment protocols.
Transcript
Play full episode